Cancer Council Victoria | Victorian Cancer Trials Link

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

Clinical summary

You may be eligible for this study if you have locally advanced or metastatic, HR+, HER2- breast cancer, and have not received any prior drug treatments for your advanced or metastatic disease.
Eligible participants will be randomly assigned into 1 of 2 treatment groups.
In Arm A (Experimental), participants will receive PF-07220060 targeted therapy plus letrozole hormone therapy.
In Arm B (Comparator), participants will receive the study doctor's choice of a CDK4/6i targeted therapy (either abemaciclib, palbociclib or ribociclib) plus letrozole hormone therapy.

Conditions

This trial is treating patients with locally advanced, metastatic or unresectable breast cancer that is HR+, HER-

Trial Acronym
FourLight-3

Trial Identifiers
NCT06760637
C4391024
2024-512925-95-00

Cancer
Breast

Age: 18+
Phase: III

For full trial details, visit trials.cancervic.org.au/details/vctl_nct06760637